Leyden Labs

A new article from Leyden Labs has been published in Scientific Reports that showcases the potential advantages of intranasal administration of monoclonal antibodies over systemic administration to protect against airborne viruses. https://lnkd.in/eyXh6Utc Specifically, we report that in vivo #influenza protection was achieved at a significantly lower #antibody dose with intranasal compared to systemic administration. Leyden Labs’ lead influenza antibody CR9114 has a unique mechanism of protection when administered intranasally that differs from what is observed systemically – intranasal antibody administration enables protection that is Fc-independent. Additionally, we observe that the unmatched breadth of CR9114 is further supported by the discovery of binding to influenza C and D alongside A and B viruses – an essential attribute for durability of protection against new, emerging strains. As Leyden Labs continues to lead innovation for mucosally-administered antibody formulations, these findings with CR9114 not only inform the ongoing development of PanFlu, but also help to shape our additional pipeline programs

A new article from Leyden Labs has been published in Scientific Reports that showcases the potential advantages of intranasal administration of monoclonal antibodies over systemic administration to protect against airborne viruses. https://lnkd.in/eyXh6Utc Specifically, we report that in vivo #influenza protection was achieved at a significantly lower #antibody dose with intranasal compared to systemic administration. Leyden Labs’ lead influenza antibody CR9114 has a unique mechanism of protection when administered intranasally that differs from what is observed systemically – intranasal antibody administration enables protection that is Fc-independent. Additionally, we observe that the unmatched breadth of CR9114 is further supported by the discovery of binding to influenza C and D alongside A and B viruses – an essential attribute for durability of protection against new, emerging strains. As Leyden Labs continues to lead innovation for mucosally-administered antibody formulations, these findings with CR9114 not only inform the ongoing development of PanFlu, but also help to shape our additional pipeline programs

LIFE has organised an excursion for Life Science & Technology students to visit Leyden Labs, an innovating company on the Leiden Bioscience park. Leyden Labs is working on intranasal products to protect people against many variants of respiratory viruses. Our students were welcomed with delicious lunch and got to listen to, former LST-student and now CEO of Leyden Labs, Koenraad Wiedhaup and the senior director Anna Beukenhorst about the origin of the company and their goals. Afterwards, we also received a tour of their workspaces and labarotoria! We would also like to thank Jacopo frallicciardi and Keira Lee R. for sharing their experiences and insights on working at Leyden Labs!

Earlier this week, Jaap Goudsmit, Chief Scientist of Leyden Labs, gave a talk on monoclonal #antibodies as preventive tools for #H5N1 outbreaks at the global consultation of the World Health Organization. Also at the meeting, Anna Beukenhorst, Senior Director of Integrated Data Analytics, moderated a panel discussion on research and development priorities for monoclonal antibodies and antivirals. Panelists touched upon resistance against approved antivirals, the challenges of producing at scale, and the lessons learned from previous pandemics. CEO Koenraad Wiedhaup commented, “We appreciate the effort of the WHO to seek global consultation on this topic. We were happy to share information about our innovative PanFlu program that uses intranasal administration of a uniquely broadly protective influenza antibody, CR9114, for prophylaxis. We already demonstrated low-dose protection against H5N1, and its breadth of protection, covering influenza H5N1 strains from 50 years ago as well as the most recent isolates. We now look forward to the R&D roadmap on avian flu that WHO plans to develop and implement.” Read more on our website: https://lnkd.in/eD7nBTHu Link to meeting information: https://lnkd.in/gcmzzCkN #influenza #avianflu #pandemic #antibodies

Following exciting advancements with new investments, scientific successes with our Mucosal Protection Platform, and clinical progress in our pipeline, we are happy to announce that we are further strengthening our senior leadership team.   We are pleased to announce the appointment of Clarissa K. to Chief Research Officer, expanding her role to lead all Research functions at Leyden Labs. Clarissa brings forth impressive scientific acumen required to guide the team from hypothesis generation to translation of scientific insights necessary to meet critical business needs. She leads the Research team with a steadfast goal to drive rapid progress in the identification and optimization of drug candidates to fight respiratory viral threats, with a strong focus on timely execution. Clarissa has spearheaded Leyden Labs’ Mucosal Protection Platform, actively identifying opportunities for value creation and IP generation for the company. Even prior to joining Leyden Labs in 2022, Clarissa always had a focus on cross-disciplinary research, incorporating computational, molecular, structural and cellular biology; this collaborative mindset feeds into her success at the leadership level now. Clarissa has a strong background in the nasal and pulmonary mucosal immune response in RSV, SARS-CoV-2, and influenza viral infections. Jaap Goudsmit, co-founder of Leyden Labs, will now serve as Chief Scientist, advising on the company’s scientific strategy, leveraging his vast background and deep expertise in virology and infectious diseases that he has previously demonstrated in both academic and industry settings. In this role, Jaap will focus on generating new scientific breakthroughs leading to new intellectual property and publications, as well as foster scientific relationships with global experts and further strengthen scientific partnerships across the globe. #leadership #team #biotech #promotion

ClavystBio CEO Khoo Shih, the latest member to join our Supervisory Board, recently discussed the growing role of Singapore in the global biotechnology industry, and the opportunities she anticipates emerging from their recent investment in Leyden Labs. 🔊 Listen to her remarks on The BioCentury This Week podcast https://lnkd.in/gvYcW8gS 🔗 Learn more about The 4th BioCentury-BayHelix East-West Biopharma Summit from March 3-5 in Singapore where Khoo Shih is among the speakers https://lnkd.in/g_p36n9f

It is an honour for us to announce that Leyden Labs is among the select set of groundbreaking companies awarded funding under #EUeic Accelerator. Only 71 out of 1211 applications were selected for funding, representing less than 6% of the submitted proposals. Reviewers recognized the importance and potential of our approach to develop non-vaccine solutions to fight back against the threat of respiratory viruses. We are grateful for both their endorsement and their investment in our mission. #biotech #EIC #EUeic #EICAccelerator #Investment #influenza #pandemic Read more from the EIC here: https://lnkd.in/de8yQbwk

As a multicultural team, it is always wonderful to learn from the traditions of our team members. Ilse (Elisabeth) Haisma said it so well below - bringing together our diverse cultural, personal, and professional backgrounds strengthens us as a team.

CEO Koenraad Wiedhaup recently discussed our goal of creating non-vaccine protection against respiratory viruses with the team MT/Sprout. See below to read more...

We are pleased to have had the honor of presenting at #JPM25 this week! CEO Koenraad Wiedhaup shared our progress in the development of non-vaccine protection against respiratory viruses, fueled by our latest funding round announced last week. He spoke of our commitment to using Mucosal Protection to stop the domino effect of viral infection. #jpm #jpmconference #biotech